Top View
- 5.01.620 Vascular Endothelial Growth Factor (VEGF) Receptor Inhibitors for Ocular Disorders
- Clinical Guideline Preferred Physician-Administered Drugs
- Macugen INN-Pegaptanib Sodium
- For Diabetic Macular Edema a Review of Agents in Clinical Trials
- Beovu (Brolucizumab-Dbll)
- Hpra Drug Safety Newsletter 9499Th Edition
- Lucentis (Ranibizumab) Macugen (Pegaptanib) Visudyne (Pegaptanib) Effective January 1, 2021
- Development of HER2-Specific Aptamer-Drug Conjugate for Breast
- Effect of Sunitinib in Treatment of Retinal Angiogenesis Induced by VEGF165 in Rabbit’S Eyes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Medical Benefit Injectable Drugs | Kaiser Permanente Washington
- Silverback Care Management CARE N' CARE Specialty Drug
- Ranibizumab and Pegaptanib for the Treatment of Age-Related Macular Degeneration Vol
- Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy
- Specialty Medications - Medical Benefit
- Medical Drug Prior Authorization List
- Macugen® (Pegaptanib)
- National Drug List Drug List — Four Tier Drug Plan
- Specialty Injectables Prior Authorization List
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
- Gpi Drug Classification Report
- Beovu® (Brolucizumab-Dbll)
- 5.01.620 Vascular Endothelial Growth Factor (VEGF) Receptor Inhibitors for Ocular Disorders
- C9050 Injection, Emapalumab-Lzsg, 1 Mg C9122
- Biologic and Other Ophthalmologic Agents Srx-0009 Policy Type ☒ Medical ☐ Administrative ☐ Payment
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments
- Allwell from Superior Healthplan (Medicare) Prior Authorization Updates
- Appendix B. Drug Codes Requiring Authorization the Following Codes Will Require Authorization for MA Effective Oct 1, 2017 Page
- Medicare Advantage Prior Authorization Drug List
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- Master Drug List
- Macugen, INN-Pegaptanib Sodium
- Ten Years of Anti-Vascular Endothelial Growth Factor Therapy
- Prior Authorization and Investigational Services List
- Pegaptanib (Macugen) Reference Number: ERX.SPMN.228 Effective Date: 01/17 Coding Implications Last Review Date: Revision Log
- 2020 Aetna Value
- Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-Doligobody)
- OCN Prior Authorization Form(Opens a New Window)
- Bevacizumab: a New KC Madhusudhana and RSB Newsom EDITORIAL Hope?
- Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Use
- Medicare Part B PA List Effective 2021
- Pegaptanib Treatment for CRVO Significant Improvement Was Seen on OCT Among Patients with Macular Edema Following CRVO
- AHFS Pharmacologic-Therapeutic Classification System
- MEDICAL DRUGS PRIOR AUTHORIZATION LIST Effective 1/22/2021
- Allwell from Buckeye Health Plan Prior Authorization Updates
- Treatments for Macular Oedema Following Central Retinal Vein Occlusion: Systematic Review
- Prior Authorization — Premium
- Pattern of Use of Intravitreal Drugs with Antiangiogenic Properties for Age-Related Macular Degeneration and Other Vascular Retinopathies
- BCBSNM Drug List Limitations, Exclusions, and Preauthorization Criteria
- 2020 Medicare Prior Authorization Code Listing (PDF)
- Aneurysm and Artery Dissection Following the Use of Vascular Endothelial Growth Factor Inhibitor: a Real-World Analysis Using a Spontaneous Reporting System
- Comparative Evaluation of Apoptotic Activity in Photoreceptor Cells After Intravitreal Injection of Bevacizumab and Pegaptanib Sodium in Rabbits
- Prescription Formulary
- Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
- Pattern of Use Drugs for AMD Treatment to Publish
- Reformulating Anti-VEGF for Extended-Release Delivery in the Treatment of Retinal Diseases
- Macugen) Reference Number: CP.PHAR.185 Effective Date: 03.01.16 Last Review Date: 02.21 Coding Implications Line of Business: Commercial, HIM, Medicaid Revision Log
- NDA 21-756 Page 4 MACUGEN (Pegaptanib Sodium Injection) DESCRIPTION MACUGEN (Pegaptanib Sodium Injection) Is a Sterile, Aqueous
- Step Therapy Part B Drugs
- Minutes of PRAC Meeting on 26-29 November 2018
- DRUG COVERAGE GUIDELINES Policy Number: PHARMACY 098.167 T0 Effective Date: November 1, 2017
- Comparison of the Efficacy and Safety of Drug Therapies for Macular Edema Secondary to Central Retinal Vein Occlusion
- Oregon Drug Use Review / Pharmacy & Therapeutics Committee
- How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? a Multiregional, Population-Based Study in the Years 2010–2016
- P & T: January 10, 2019
- Blue Cross Medicare Advantage Specialty Pharmacy Code List
- Medicare Parb B Drugs with Part D Step Therapy
- Macugen, INN-Pegaptanib Sodium
- PHYSICIAN ADMINISTERED DRUG PROGRAM (PADP) FEE SCHEDULE EFFECTIVE JANUARY 1, 2021 the Inclusion of a Rate on This Table Does Not Guarantee That a Service Is Covered